The present invention relates to: a biomarker composition for predicting the prognosis of brain disease caused by microplastic exposure; and a use thereof. More particularly, it was confirmed that polyethylene microspheres (PS) in a mouse animal model orally administered with the PS penetrate brain tissue to change the level of metabolites inside the brain tissue and the diversity of intestinal microorganisms, thereby causing brain disease, and thus the present invention is intended to provide a biomarker composition for predicting the prognosis of brain disease caused by microplastic exposure, and a method for predicting the prognosis of brain disease using same.

Disclosed herein is a core-shell nanoparticle exhibiting aggregation induced emission (AIE) properties. According to the embodiments of the present disclosure, the core-shell nanoparticle comprises a core and a shell layer encapsulating the core, in which the core comprises a polymeric matrix and one or more tetraphenylethane (TPE) embedded in the polymeric matrix. Preferably, the polymeric matrix is made of a hydrophobic polymer, and the shell layer is made of a hydrophilic polymer. Also disclosed herein are methods of producing the core-shell nanoparticle, and methods of detecting an extracellular polymeric substance (EPS) produced by a microorganism via using the core-shell nanoparticle.

Disclosed herein is a core-shell nanoparticle exhibiting aggregation induced emission (AIE) properties. According to the embodiments of the present disclosure, the core-shell nanoparticle comprises a core and a shell layer encapsulating the core, in which the core comprises a polymeric matrix and one or more tetraphenylethane (TPE) embedded in the polymeric matrix. Preferably, the polymeric matrix is made of a hydrophobic polymer, and the shell layer is made of a hydrophilic polymer. Also disclosed herein are methods of producing the core-shell nanoparticle, and methods of detecting an extracellular polymeric substance (EPS) produced by a microorganism via using the core-shell nanoparticle.

The present invention relates to 3D brain organoids, uses thereof, methods and culture medium for generating such organoids. An aspect of the invention provides brain organoids and methods of generating such organoids with bilaterally symmetric optic vesicles, containing both neuronal and non-neuronal cell types, and exhibiting functional circuitry. These organoids can be generated within short time intervals (e.g., 50 days) and therefore are useful for medical modelling and applications.

The microfluidic chip according to an embodiment of the present invention may include a plate, a bridge channel formed in intaglio on one side of the plate, an inlet formed through the plate to communicate with one end of the bridge channel, an outlet formed through the plate to communicate with the other end of the bridge channel, and at least one well extending in an outward direction of the plate from the bridge channel to provide a space, wherein the bridge channel may be in the form of a curved line, a bent line, an arc, a circle, a spiral, or a polygon.

Methods are described for treating aqueous solutions, including wastewater, to remove nitrogen-containing compounds using electrochemical processes. The method may be conducted electrolytically under an applied voltage or using endogenous current in a fuel cell arrangement. In some embodiments, energy is reclaimed in the form of hydrogen, methane, and other hydrocarbons or organic molecules. Microorganisms may be used as the catalyst for oxidation of the nitrogen-containing compound and/or reduction of hydrogen ions, carbon dioxide, or bicarbonate. Anaerobic or low-oxygen conditions may be used in the zone.

An object of the present invention is to provide a human astrocyte cell population that is differentiated from astrocyte progenitor cells derived from human iPS cells, a manufacturing method for the human astrocyte cell population; and an evaluation method for a test substance using the human astrocyte cell population. According to the present invention, there is provided a human astrocyte cell population that is differentiated from astrocyte progenitor cells derived from human iPS cells, the human astrocyte cell population including at least 90% of human astrocytes, in which in the human astrocytes, a) CDKN2A is positive, b) at least one gene marker selected from the group consisting of IGFBP5, NNMT, HLA-DRB1, and HLA-DRB5 is positive, and c) an expression level of C3, which is standardized with GAPDH of a reference gene, is 0.05 copies/copies or less.

A method for assessing drug-resistant microorganism includes the following steps. A model establishing step is performed so as to obtain an antibiotic resistance assessing classifier. A test sample is provided. A sample pre-processing step is performed so as to obtain a processed sample. An analysis step is performed so as to obtain a target mass spectrum data. A spectrum pre-processing step is performed so as to obtain a normalized target mass spectrum data. A feature extraction step is performed so as to obtain a spectrum feature. An assessing step is performed, wherein the spectrum feature is analyzed by the antibiotic resistance assessing classifier so as to output an assessed result of drug-resistant microorganism, and the assessed result of drug-resistant microorganism is for assessing whether the test microorganism is a drug-resistant microorganism or not.

A method for assessing drug-resistant microorganism includes the following steps. A model establishing step is performed so as to obtain an antibiotic resistance assessing classifier. A test sample is provided. A sample pre-processing step is performed so as to obtain a processed sample. An analysis step is performed so as to obtain a target mass spectrum data. A spectrum pre-processing step is performed so as to obtain a normalized target mass spectrum data. A feature extraction step is performed so as to obtain a spectrum feature. An assessing step is performed, wherein the spectrum feature is analyzed by the antibiotic resistance assessing classifier so as to output an assessed result of drug-resistant microorganism, and the assessed result of drug-resistant microorganism is for assessing whether the test microorganism is a drug-resistant microorganism or not.

Provided is a three-dimensional tissue, including: a first cellular region including cells of a first type; and a second cellular region including cells of a second type different from the first type, wherein the cells of the first type are cells that emit light by chemiluminescence, bioluminescence, or fluorescence in response to an external stimulus.